Eli Lilly's JAK inhibitor demonstrated 80% scalp hair regrowth in 42.4% of adolescents with severe alopecia areata after just 36 weeks of treatment, outperforming placebo in the Phase 3 BRAVE-AA-PEDS trial.
Individuals with androgenetic alopecia face an increased risk of depression, with an odds ratio of 1.015, according to a new Mendelian randomization study.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A genome-wide meta-analysis identified novel genetic interactions between ERAP1 and MHC class I alleles, highlighting their role in frontal fibrosing alopecia susceptibility.